Chronic kidney disease

FibroGen to Present at Jefferies Healthcare Conference

Retrieved on: 
Thursday, May 26, 2022 - 12:00pm

SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT.

Key Points: 
  • SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT.
  • A live audio webcast of the event will be available on the Events & Presentations section of the FibroGen Investors webpage at www.fibrogen.com.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of potential first-in-class therapeutics.
  • FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space.

Global Dialysis Devices and Equipment Market Report 2022: Market is Expected to Grow to $6 Billion in 2026 - Long-term Forecast to 2031 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 26, 2022 - 11:16am

The dialysis devices and equipment market consist of the sale of dialysis devices and equipment-related services.

Key Points: 
  • The dialysis devices and equipment market consist of the sale of dialysis devices and equipment-related services.
  • The main products of dialysis devices and equipment are hemodialysis devices and peritoneal dialysis devices.
  • Global Dialysis Devices And Equipment Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
    6.2.
  • Global Dialysis Devices And Equipment Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022

Retrieved on: 
Wednesday, May 25, 2022 - 9:15pm

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will be participating in the 19th Annual Craig-Hallum Institutional Investor Conference being held virtually on Wednesday, June 1, 2022.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will be participating in the 19th Annual Craig-Hallum Institutional Investor Conference being held virtually on Wednesday, June 1, 2022.
  • Management will be available to participate in one-on-one meetings.
  • Investors and attendees that would like to schedule a meeting with DiaMedicas management can contact their Craig-Hallum representative to arrange a meeting.
  • DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases.

juli Welcomes Michael Seggev as Senior Vice President/Commercial

Retrieved on: 
Wednesday, May 25, 2022 - 2:34pm

BOSTON, May 25, 2022 /PRNewswire/ -- juli , the AI-powered digital health platform that delights and engages consumers to power their own health while offering their healthcare providers insights from sub-episodic health data, today announced the appointment of Michael Seggev as Senior Vice President/Commercial.

Key Points: 
  • BOSTON, May 25, 2022 /PRNewswire/ -- juli , the AI-powered digital health platform that delights and engages consumers to power their own health while offering their healthcare providers insights from sub-episodic health data, today announced the appointment of Michael Seggev as Senior Vice President/Commercial.
  • Seggev will be responsible for leading U.S. and global commercialization of juli and will report directly to CEO Bettina Hein.
  • Seggev brings over 25 years of commercialization experience in healthcare, including B2B go-to-market planning and launch leadership at two disruptive digital health startups.
  • "I look forward to working with Michael to amplify our team's ability to drive the value of juli with these key customers."

Global Chronic Kidney Disease (CKD) Pipeline Landscape Report 2022: Comprehensive Insights About 50+ Companies and 50+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 25, 2022 - 1:39pm

This "Chronic-kidney-disease-chronic-renal-failure- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic-kidney-disease-chronic-renal-failure pipeline landscape.

Key Points: 
  • This "Chronic-kidney-disease-chronic-renal-failure- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic-kidney-disease-chronic-renal-failure pipeline landscape.
  • A detailed picture of the Chronic-kidney-disease-chronic-renal-failure pipeline landscape is provided which includes the disease overview and Chronic-kidney-disease-chronic-renal-failure treatment guidelines.
  • The assessment part of the report embraces, in depth Chronic-kidney-disease-chronic-renal-failure commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic-kidney-disease-chronic-renal-failure R&D.

Chinook Therapeutics Announces Pricing of a $105 Million Public Offering

Retrieved on: 
Wednesday, May 25, 2022 - 2:57am

SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share.

Key Points: 
  • SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share.
  • The gross proceeds to Chinook from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chinook, are expected to be $105 million.
  • Chinook has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock in connection with the public offering.
  • The offering is expected to close on or about May 27, 2022, subject to the satisfaction of customary closing conditions.

Chinook Therapeutics Announces Proposed Public Offering

Retrieved on: 
Tuesday, May 24, 2022 - 9:02pm

In addition, Chinook intends to grant the underwriters a 30-day option to purchase additional shares of its common stock offered in the public offering at the public offering price less underwriting discounts and commissions.

Key Points: 
  • In addition, Chinook intends to grant the underwriters a 30-day option to purchase additional shares of its common stock offered in the public offering at the public offering price less underwriting discounts and commissions.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • SVB Securities, Cantor and William Blair are acting as joint book-running managers for the proposed offering.
  • Wedbush PacGrow is acting as lead manager for the proposed offering.

Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022

Retrieved on: 
Friday, May 20, 2022 - 3:25pm

We believe this dataset provides strong readthrough to the topline proteinuria data from the phase 3 ALIGN trial expected in 2023.

Key Points: 
  • We believe this dataset provides strong readthrough to the topline proteinuria data from the phase 3 ALIGN trial expected in 2023.
  • Key highlights from the presentation include the following:
    In the IgAN cohort, median baseline 24-hour urine protein excretion was 1.17 g/day.
  • As of the April 22, 2022 data cutoff, atrasentan has been well-tolerated to date in patients with IgAN, with no treatment-related SAEs.
  • Chinooks lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.

ProKidney to present at upcoming investor conferences

Retrieved on: 
Friday, May 20, 2022 - 2:00pm

Investors attending the Jefferies Healthcare Conference who wish to meet with ProKidney management are encouraged to contact their Jefferies representative.

Key Points: 
  • Investors attending the Jefferies Healthcare Conference who wish to meet with ProKidney management are encouraged to contact their Jefferies representative.
  • ProKidney, a pioneer in the treatment of CKD through innovation in cellular therapy, was founded in 2015 after a decade of research.
  • On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III (Nasdaq: DNAC).
  • Neither ProKidney nor SCS gives any assurance that either ProKidney or SCS, or the combined company, will achieve its expectations.

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

Retrieved on: 
Thursday, May 19, 2022 - 7:05am

Patients in Cohort 1 initially received an intravenous (IV) dose of 450 mg of BION-1301 every two weeks.

Key Points: 
  • Patients in Cohort 1 initially received an intravenous (IV) dose of 450 mg of BION-1301 every two weeks.
  • As of the May 6, 2022 data cutoff, BION-1301 has been well-tolerated, with no serious adverse events or treatment discontinuations due to adverse events.
  • BION-1301 durably reduced serum IgA and IgM levels, and to a lesser extent, IgG levels in all patients.
  • Chinooks lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.